Zaměstnanci společnosti Shanghai Junshi Biosciences Co
Jaká je hodnota metriky Zaměstnanci společnosti Shanghai Junshi Biosciences Co?
Hodnota metriky Zaměstnanci společnosti Shanghai Junshi Biosciences Co., Ltd. je 2,805
Jaká je definice metriky Zaměstnanci?
Zaměstnanci (Employees) je počet zaměstnanců společnosti, kteří pracují za plat odpovídající typu práce a sektoru, v němž pracují.
Employment is a relationship between two parties, usually based on a contract where work is paid for, where one party, which may be a corporation, for profit, not-for-profit organization, co-operative or other entity is the employer and the other is the employee.
Employees in some fields or sectors may receive gratuities, bonus payment or stock options. In some types of employment, employees may receive benefits in addition to payment. Benefits can include health insurance, housing, disability insurance or use of a gym. Employment is typically governed by employment laws or regulations or legal contracts.
Zaměstnanci společností v sektoru Health Care sektor na OTC ve srovnání se společností Shanghai Junshi Biosciences Co
Čemu se věnuje společnost Shanghai Junshi Biosciences Co?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Firmy s metrikou zaměstnanci podobnou společnosti Shanghai Junshi Biosciences Co
- Hodnota metriky Zaměstnanci společnosti Nuvasive Inc je 2,800
- Hodnota metriky Zaměstnanci společnosti Four Seas Mercantile je 2,800
- Hodnota metriky Zaměstnanci společnosti Ansys je 2,800
- Hodnota metriky Zaměstnanci společnosti Greaves Cotton je 2,800
- Hodnota metriky Zaměstnanci společnosti HC2 Inc je 2,803
- Hodnota metriky Zaměstnanci společnosti Yuanda China je 2,804
- Hodnota metriky Zaměstnanci společnosti Shanghai Junshi Biosciences Co je 2,805
- Hodnota metriky Zaměstnanci společnosti Dhampur Sugar Mills je 2,806
- Hodnota metriky Zaměstnanci společnosti Freedom je 2,810
- Hodnota metriky Zaměstnanci společnosti Neles Oyj je 2,812
- Hodnota metriky Zaměstnanci společnosti Solocal je 2,813
- Hodnota metriky Zaměstnanci společnosti Interpublic Of Cos je 2,815
- Hodnota metriky Zaměstnanci společnosti Beijing Jingneng Clean Co je 2,817